AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12572702 — intervention group
Group type: COMPARATOR
Intervention: Incidence screening
Number of subjects: 0
Study 12572702 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy before surgery
Number of subjects: 0
Study 12572702 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy following surgery
Number of subjects: 0
Study 12572702 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 0
Study 12572702 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 0
Study 12572702 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) scanning
Number of subjects: 0
Study 10469812 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription for 2 quarts of ORS filled for free at on-site pharmacy plus written instructions
Number of subjects: 479
Study 10469812 — intervention group
Group type: COMPARATOR
Intervention: Written instructions alone
Number of subjects: 479
Study 8912770 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with obstructive sleep apnea (OSA)
Number of subjects: 19
Study 8912770 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 19
Study 1859751 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg kg‐1
Number of subjects: 30
Study 1859751 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.1 mg kg‐1
Number of subjects: 30
Study 1859751 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.5 mg kg‐1
Number of subjects: 30
Study 1859751 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1.0 mg kg‐1
Number of subjects: 30
Study 1859751 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 0.05 mg kg‐1 (control group)
Number of subjects: 30
Study 1859751 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine vs Edrophonium
Number of subjects: 30
Study 1859751 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling doses of anticholinesterases
Number of subjects: 30
Study 6336923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic trousers
Number of subjects: 136
Study 6336923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic trousers (VF)
Number of subjects: 136
Study 6336923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic trousers (PIVR)
Number of subjects: 136
Study 6336923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic trousers (AS)
Number of subjects: 136
Study 6336923 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 6336923 — intervention group
Group type: COMPARATOR
Intervention: Control group (VF)
Number of subjects: 136
Study 6336923 — intervention group
Group type: COMPARATOR
Intervention: Control group (PIVR)
Number of subjects: 136
Study 6336923 — intervention group
Group type: COMPARATOR
Intervention: Control group (AS)
Number of subjects: 136
Study 31524782 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:8 work-to-rest ratio
Number of subjects: 36
Study 31524782 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:10 work-to-rest ratio
Number of subjects: 36
Study 31524782 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:12 work-to-rest ratio
Number of subjects: 36
Study 31524782 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-training)
Number of subjects: 36
Study 27989618 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-mg sustained-release pelubiprofen
Number of subjects: 24
Study 27989618 — intervention group
Group type: EXPERIMENTAL
Intervention: trans-alcohol pelubiprofen (major active metabolite)
Number of subjects: 24
Study 27989618 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-mg sustained-release eperisone hydrochloride
Number of subjects: 24
Study 26390073 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Auricular Point Acupressure (APA), n = 16
Number of subjects: 31
Study 26390073 — intervention group
Group type: COMPARATOR
Intervention: Control Auricular Point Acupressure (sham treatment), n = 15
Number of subjects: 31
Study 25552113 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged flow-aspiration drainage of laparotomy wounds
Number of subjects: 254
Study 25552113 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (in layers, tightly)
Number of subjects: 254
Study 23107083 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy options counseling workshop
Number of subjects: 105
Study 23107083 — intervention group
Group type: COMPARATOR
Intervention: Preworkshop group (control)
Number of subjects: 105
Study 19544815 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced excursive occlusal contacts on one tooth using a fine grain diamond bur.
Number of subjects: 39
Study 19544815 — intervention group
Group type: COMPARATOR
Intervention: Non‐adjusted teeth (control group).
Number of subjects: 39
Study 17460608 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 97
Study 17460608 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide
Number of subjects: 97
Study 17460608 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 97
Study 17460608 — intervention group
Group type: EXPERIMENTAL
Intervention: NCC alanine 264 allele (Gly264Ala)
Number of subjects: 97
Study 17460608 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant alleles of rs5,723 (Leu649Leu) and rs5,729 in SCNN1G
Number of subjects: 97
Study 17460608 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended haplotype homozygosity of NCC alanine 264 allele
Number of subjects: 97
Study 14760121 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP
Number of subjects: 100
Study 14760121 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 100
Study 14760121 — intervention group
Group type: COMPARATOR
Intervention: MOPP and ABVD
Number of subjects: 100
Study 11473882 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (238 +/- 50 microg)
Number of subjects: 20
Study 11473882 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sufentanil (160 +/- 32 microg)
Number of subjects: 20
Study 11473882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Epidural and IV sufentanil)
Number of subjects: 20
Study 9533424 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 45
Study 9533424 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting nifedipine
Number of subjects: 45
Study 9533424 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-releasing nifedipine
Number of subjects: 45
Study 8037104 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 2.5 mg twice per day for 7 days (mean 6.1, range 2 to 7, median 7)
Number of subjects: 7487
Study 8037104 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 2.5 mg twice per day
Number of subjects: 7487
Study 2928734 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal gastroplasty (HGP)
Number of subjects: 45
Study 2928734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical banded gastroplasty (VBGP)
Number of subjects: 45
Study 2928734 — intervention group
Group type: COMPARATOR
Intervention: Control (diet alone)
Number of subjects: 45
Study 29703051 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HES (130/0.42)
Number of subjects: 63
Study 29703051 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES (130/0.42)
Number of subjects: 63
Study 29703051 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid
Number of subjects: 63
Study 29214999 — intervention group
Group type: EXPERIMENTAL
Intervention: Engineered KGSADH variants
Number of subjects: 0
Study 29214999 — intervention group
Group type: COMPARATOR
Intervention: Wild-type KGSADH
Number of subjects: 0
Study 26305869 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message intervention to promote alertness
Number of subjects: 100
Study 23154155 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) meal providing 2g/kg BM of carbohydrate
Number of subjects: 7
Study 23154155 — intervention group
Group type: COMPARATOR
Intervention: Low Glycemic Index (LGI) meal providing 2g/kg BM of carbohydrate
Number of subjects: 7
Study 21542026 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg alcohol
Number of subjects: 40
Study 21542026 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 40
Study 18438229 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric exercises including two‐foot ankle hops, 15‐cm cone hops, tuck, pike, box jumps, one‐ and two‐leg vertical jump and reach, squat jumps with approximately 30% of their 1RM squat load, and 30‐ and 61‐cm depth jumps.
Number of subjects: 23
Study 18438229 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric exercises (specific exercises not detailed)
Number of subjects: 23
Study 17090988 — intervention group
Group type: EXPERIMENTAL
Intervention: Yakson therapy (5 minutes of hand laying on the back and caressing the abdomen)
Number of subjects: 32
Study 17090988 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 32
Study 17090988 — intervention group
Group type: EXPERIMENTAL
Intervention: Yakson therapy
Number of subjects: 32
Study 17090988 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 12576164 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg/kg/min infusion of valproate sodium injection
Number of subjects: 112
Study 12576164 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg/min infusion of valproate sodium injection
Number of subjects: 112
Study 10551687 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab plus low-dose heparin
Number of subjects: 100
Study 10551687 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose heparin
Number of subjects: 100
Study 8913487 — intervention group
Group type: EXPERIMENTAL
Intervention: Atevirdine 600 mg three times a day for 12 weeks
Number of subjects: 30
Study 8913487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1991610 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Radiography (CR) using imaging plate
Number of subjects: 0
Study 1991610 — intervention group
Group type: COMPARATOR
Intervention: Conventional screen/film system
Number of subjects: 0
Study 6193346 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT)
Number of subjects: 24
Study 6193346 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide (PT)
Number of subjects: 24
Study 6193346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31911605 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sample multivariable Mendelian randomization based on Bayesian model averaging (MR-BMA)
Number of subjects: 0
Study 31911605 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of publicly-available summarized data on metabolites
Number of subjects: 0
Study 29880491 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily)
Number of subjects: 80
Study 29880491 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg every 2 weeks)
Number of subjects: 80
Study 28079755 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zeaxanthin per day
Number of subjects: 8
Study 28079755 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg zeaxanthin per day
Number of subjects: 8
Study 28079755 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study 26366802 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin desensitization (AD)
Number of subjects: 16
Study 23478167 — intervention group
Group type: EXPERIMENTAL
Intervention: Active RPSS with daily motor training
Number of subjects: 20
Study 23478167 — intervention group
Group type: COMPARATOR
Intervention: Sham RPSS with daily motor training
Number of subjects: 20
Study 21501665 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation training (MM) for 8 weeks
Number of subjects: 0
Study 21501665 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18199731 — intervention group
Group type: EXPERIMENTAL
Intervention: High IGF‐I/IGFBP‐3 ratio
Number of subjects: 137
Study 18199731 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP‐3
Number of subjects: 137
Study 17156423 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (one-hour supervised session twice a week and daily home exercises)
Number of subjects: 58
Study 17156423 — intervention group
Group type: COMPARATOR
Intervention: Standardised rest
Number of subjects: 58
Study 14660201 — intervention group
Group type: EXPERIMENTAL
Intervention: JTMT with the right hand (R)
Number of subjects: 0
Study 14660201 — intervention group
Group type: EXPERIMENTAL
Intervention: JTMT with the left hand (L)
Number of subjects: 0
Study 14660201 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror version of JTMT with the left hand (M)
Number of subjects: 0
Study 14660201 — intervention group
Group type: EXPERIMENTAL
Intervention: Part A (first examination)
Number of subjects: 0
Study 14660201 — intervention group
Group type: EXPERIMENTAL
Intervention: Part A (second and third performances)
Number of subjects: 0
Study 10834413 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 882
Study 10834413 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (HI)
Number of subjects: 882
Study 10834413 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp) and Regular human insulin (HI)
Number of subjects: 882
Study 9357345 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month relapse prevention program
Number of subjects: 539
Study 9357345 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic community program
Number of subjects: 539
Study 9357345 — intervention group
Group type: COMPARATOR
Intervention: 12-month therapeutic community program
Number of subjects: 539
Study 9357345 — intervention group
Group type: COMPARATOR
Intervention: 6-month therapeutic community program
Number of subjects: 539
Study 9357345 — intervention group
Group type: COMPARATOR
Intervention: 3-month relapse prevention program
Number of subjects: 539
Study 7934683 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 20
Study 7934683 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anaesthesia
Number of subjects: 20
Study 3533134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (oral administration)
Number of subjects: 0
Study 3533134 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine (intravenous administration)
Number of subjects: 0
Study 3533134 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 31335871 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet
Number of subjects: 1252
Study 31335871 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1252
Study 29976161 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial IV bolus (6 g loading dose with 2 g bolus every 2 h using a Springfusor® pump)
Number of subjects: 200
Study 29976161 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (4 g loading dose with 1 g/hr. continuous infusion)
Number of subjects: 200
Study 29976161 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial IV bolus
Number of subjects: 200
Study 29976161 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion
Number of subjects: 200
Study 26882922 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg × 3)
Number of subjects: 40
Study 26882922 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen (50 mg × 3)
Number of subjects: 40
Study 24253285 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwalk virus (various dosages)
Number of subjects: 57
Study 24253285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 24253285 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwalk virus (dosage for secretor-positive blood group O or A)
Number of subjects: 57
Study 24253285 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwalk virus (dosage for all secretor-positive persons)
Number of subjects: 57
Study 24253285 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwalk virus
Number of subjects: 57
Study 23875569 — intervention group
Group type: EXPERIMENTAL
Intervention: Odor-object identity
Number of subjects: 0
Study 23875569 — intervention group
Group type: EXPERIMENTAL
Intervention: Odor valence and edibility decision response times
Number of subjects: 0
Study 23875569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low road and high road processing
Number of subjects: 0
Study 20533760 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine lozenges (8 mg), n = 123
Number of subjects: 246
Study 20533760 — intervention group
Group type: COMPARATOR
Intervention: Commercial pastilles (8 mg), n = 123
Number of subjects: 246
Study 18259029 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 4963
Study 18259029 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 4963
Study 16840654 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise challenge
Number of subjects: 18
Study 16840654 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator administration
Number of subjects: 18
Study 16840654 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements in subjects with EIB
Number of subjects: 18
Study 12568852 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1beta stimulation of cultured stromal cells
Number of subjects: 0
Study 12568852 — intervention group
Group type: COMPARATOR
Intervention: Recombinant IL‐1 receptor antagonist
Number of subjects: 0
Study 12568852 — intervention group
Group type: COMPARATOR
Intervention: Anti‐IL‐1beta antibody
Number of subjects: 0
Study 10867375 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with specific allergens (subcutaneous administration of the vaccine)
Number of subjects: 105
Study 10867375 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 105
Study 8623949 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-dose fentanyl anesthesia (LDFA)
Number of subjects: 40
Study 8623949 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-dose fentanyl anesthesia (SDFA)
Number of subjects: 40
Study 1423201 — intervention group
Group type: EXPERIMENTAL
Intervention: CYADIC (cyclophosphamide, doxorubicin, and dacarbazine)
Number of subjects: 0
Study 1423201 — intervention group
Group type: EXPERIMENTAL
Intervention: CYVADIC (vincristine added to CYADIC)
Number of subjects: 0
Study 1423201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dose of cyclophosphamide < 7.5 g/m2
Number of subjects: 0
Study 1423201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dose of cyclophosphamide > 7.5 g/m2
Number of subjects: 0
Study 3804185 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 5 mg daily
Number of subjects: 6
Study 3804185 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg daily
Number of subjects: 6
Study 3804185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29945562 — intervention group
Group type: EXPERIMENTAL
Intervention: nal‐IRI + 5‐FU/LV
Number of subjects: 56
Study 29945562 — intervention group
Group type: EXPERIMENTAL
Intervention: nab‐P + Gem followed by nal‐IRI + 5‐FU/LV
Number of subjects: 56
Study 27776761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative low-frequency electroacupuncture
Number of subjects: 0
Study 27776761 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electroacupuncture)
Number of subjects: 0
Study 25700144 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention (electronic educational and decision support tools)
Number of subjects: 103
Study 25700144 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 103
Study 21753734 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen sponge and xenogeneic bone grafts
Number of subjects: 20
Study 21753734 — intervention group
Group type: COMPARATOR
Intervention: Control group (no special treatments for the extraction socket)
Number of subjects: 20
Study 16219019 — intervention group
Group type: EXPERIMENTAL
Intervention: IGT(fast) group
Number of subjects: 22
Study 16219019 — intervention group
Group type: EXPERIMENTAL
Intervention: IGT(slow) group
Number of subjects: 22
Study 12089651 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0
Study 9684190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual birch pollen extract
Number of subjects: 41
Study 9684190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 7979841 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fluvastatin sodium once daily
Number of subjects: 207
Study 7979841 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg fluvastatin sodium twice daily
Number of subjects: 207
Study 7979841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 2661389 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol per day
Number of subjects: 38
Study 2661389 — intervention group
Group type: COMPARATOR
Intervention: 25 mg hydrochlorothiazide
Number of subjects: 38
Study 2661389 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of responders and non-responders within metoprolol group
Number of subjects: 38
Study 2661389 — intervention group
Group type: COMPARATOR
Intervention: Comparison of responders and non-responders within hydrochlorothiazide group
Number of subjects: 38
Study 2661389 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal analyses
Number of subjects: 38
Study 1182489 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal test (Miller Analogy Test) with motivation
Number of subjects: 24
Study 1182489 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial test (Street) with motivation
Number of subjects: 24
Study 1182489 — intervention group
Group type: COMPARATOR
Intervention: Verbal test (Miller Analogy Test) without motivation
Number of subjects: 24
Study 1182489 — intervention group
Group type: COMPARATOR
Intervention: Spatial test (Street) without motivation
Number of subjects: 24
Study 12208924 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoch stem (porous-coated composite stem with reduced stiffness)
Number of subjects: 68